XSHG
600436
Market cap10bUSD
Oct 09, Last price
119.82CNY
1D
1.38%
1Q
2.37%
Jan 2017
161.79%
IPO
93.16%
Name
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Chart & performance
P/E
33.49
P/S
8.03
EPS
3.58
Div yield, %
2.72%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
6.69%
Revenues
9.00b
-16.56%
Net income
2.16b
-27.49%
CFO
77m
-94.14%
Dividend
Jul 31, 20261.57 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a Chinese company, headquartered in Zhangzhou, that specializes in the production and distribution of traditional Chinese medicines. Its offerings, predominantly sold under the renowned Pien Tze Huang brand, reach consumers both domestically within China and across international markets. Beyond its core pharmaceutical products, the company's expansive portfolio encompasses health and wellness items, beauty care products, household chemical goods, a variety of medical devices, and nutritional supplements. The firm operates as a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.
Key people
Zhihui Lin
Chairman of the Board · since 2023
Wei He
Acting Chief Accounting Officer, Deputy General Manager, Secretary of the Board · since 2025
Jinming Huang
General Manager, Director · since 2023
Zexiu Zhang
Deputy General Manager · since 2024
Yixiong Shi
Deputy General Manager · since 2025
Wenning Lai
Director · since 2022
Director · since 2025
Haipeng Yang
Chief Accounting Officer, Director · since 2022
Lei Chen
Independent Director · since 2023
Independent Director · since 2022
Zhipeng Fan
Independent Director · since 2018
Zhengda Tian
Independent Director · since 2024
Lei Zhang
Independent Director · since 2023
Headquarters & legal address
福建省漳州市芗城区琥珀路1号
漳州市, FJ 363000
CN
漳州市, FJ 363000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||